<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="17748">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02875834</url>
  </required_header>
  <id_info>
    <org_study_id>D9480C00002</org_study_id>
    <nct_id>NCT02875834</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia</brief_title>
  <acronym>HARMONIZE GL</acronym>
  <official_title>A Phase 3 Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ZS, in Patients With Hyperkalemia-HARMONIZE Global</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of two different doses (5 and 10 g) of ZS orally administered once
      daily (qd) vs placebo in maintaining normokalemia in initially hyperkalemic patients having
      achieved normokalemia following two days of initial ZS therapy (10g TID).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2017</start_date>
  <completion_date type="Anticipated">February 12, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 12, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Least Square Mean S-K level on days 8-29</measure>
    <time_frame>Through 28-day randomized treatment study phase day 8-29</time_frame>
    <description>Comparison between placebo and the active ZS treatment groups (each dose group will be sequentially compared with placebo, starting with the highest and ending with the lowest dose) with regard to the mean S-K level during the 28-day randomized treatment study phase Days 8-29</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving normokalemia</measure>
    <time_frame>Through 48-hour initial phase</time_frame>
    <description>Proportion of patients who achieve normokalemia during the initial phase at 24 and 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exponential rate of change in S-K levels</measure>
    <time_frame>Through 48-hour initial phase</time_frame>
    <description>Exponential rate of change in S-K levels (blood) during the 48-hour open-label initial phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in S-K levels</measure>
    <time_frame>Through 48-hour initial phase</time_frame>
    <description>Change (absolute and percent change) from baseline in S-K levels at all measured time intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to normalization in S-K levels</measure>
    <time_frame>Through 48-hour initial phase</time_frame>
    <description>Time to normalization in S-K levels in 48-hour open-label initial phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients remaining normokalemic</measure>
    <time_frame>Through 28-day randomized treatment phase</time_frame>
    <description>The proportion of patients who remain normokalemic (as defined by S-K between 3.5-5.0 mmol/l, inclusive) at the end of the 28-day randomized treatment study phase and during the 28-day randomized treatment study phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days patients remain normokalemic</measure>
    <time_frame>Through 28-day randomized treatment phase</time_frame>
    <description>The number of days patients remain normokalemic during the 28-day randomized treatment study phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change and mean percent change in S-K levels</measure>
    <time_frame>Through 28-day randomized treatment phase</time_frame>
    <description>The mean change and mean percent change in S-K levels evaluated relative to both baselines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hyperkalemia</measure>
    <time_frame>Through 28-day randomized treatment phase</time_frame>
    <description>The time to hyperkalemia (defined as S-K ≥ 5.1mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes in S-Aldosterone and P Renin levels</measure>
    <time_frame>Through 28-day randomized treatment phase</time_frame>
    <description>The mean changes in S-Aldosterone and P-Renin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported health state (EQ-5D questionnaire)</measure>
    <time_frame>Through study completion, an average of 37 days</time_frame>
    <description>Evaluate health state of patients using EQ-5D</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum calcium (S-Ca)</measure>
    <time_frame>Through study completion, an average of 37 days</time_frame>
    <description>To evaluate the effect of ZS on S-Ca in both 48-hour open label initial phase and 28-day randomized treatment study phase</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum magnesium (S-Mg)</measure>
    <time_frame>Through study completion, an average of 37 days</time_frame>
    <description>To evaluate the effect of ZS on S-Mg in both 48-hour open label initial phase and 28-day randomized treatment study phase</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum sodium (S-Na)</measure>
    <time_frame>Through study completion, an average of 37 days</time_frame>
    <description>To evaluate the effect of ZS on S-Na in both 48-hour open label initial phase and 28-day randomized treatment study phase</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum phosphate (S-PO4)</measure>
    <time_frame>Through study completion, an average of 37 days</time_frame>
    <description>To evaluate the effect of ZS on S-PO4 in both 48-hour open label initial phase and 28-day randomized treatment study phase</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum bicarbonate (S-HCO3)</measure>
    <time_frame>Through study completion, an average of 37 days</time_frame>
    <description>To evaluate the effect of ZS on S-HCO3 in both 48-hour open label initial phase and 28-day randomized treatment study phase</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood urea nitrogen (BUN)</measure>
    <time_frame>Through study completion, an average of 37 days</time_frame>
    <description>To evaluate the effect of ZS on BUN in both 48-hour open label initial phase and 28-day randomized treatment study phase</description>
  </other_outcome>
  <other_outcome>
    <measure>AEs, SAEs, vital signs,physical examinations,ECG and clinical laboratory evaluations</measure>
    <time_frame>Through study completion, an average of 37 days</time_frame>
    <description>To evaluate the safety and tolerability profiles of ZS in both 48-hour open label initial phase and 28-day randomized treatment study phase</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">255</enrollment>
  <condition>Hyperkalemia</condition>
  <arm_group>
    <arm_group_label>Sodium Zirconium Cyclosilicate (ZS) 5g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Zirconium Cyclosilicate (ZS) 10g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Zirconium Cyclosilicate (ZS) 10g</intervention_name>
    <description>Suspension administered 10g orally three times per day, in the first 48-hour of the study for all patients (48-hour open label initial phase)</description>
    <arm_group_label>Sodium Zirconium Cyclosilicate (ZS) 10g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Zirconium Cyclosilicate (ZS) 5g</intervention_name>
    <description>Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
    <arm_group_label>Sodium Zirconium Cyclosilicate (ZS) 5g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Zirconium Cyclosilicate (ZS) 10g</intervention_name>
    <description>Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
    <arm_group_label>Sodium Zirconium Cyclosilicate (ZS) 10g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Female and male patients aged ≥18 and ≤ 90 years

          -  Two consecutive i-STAT potassium values, measured 60-minutes (± 10 minutes) apart,
             both ≥ 5.1 mmol/l and measured within 1 day of the first ZS dose on 48-hour
             open-label initial phase Day 1

          -  Ability to have repeated blood draws or effective venous catheterization

          -  Female patients must be 1 year post-menopausal, surgically sterile, or using an
             acceptable method of contraception for the duration of the study and for 3 months
             after the last dose of ZS/matching placebo to prevent pregnancy.

        Exclusion Criteria:

          -  Involvement in the planning and/or conduct of the study

          -  Participation in another clinical study with an investigational product during the
             last 3 months

          -  Pseudohyperkalemia signs and symptoms

          -  Patients treated with lactulose, xifaxan (rifaximin) or other non-absorbed
             antibiotics for hyperammonemia within 7 days prior to the first dose of study drug

          -  Patients treated with resins,calcium acetate,calcium carbonate, or lanthanum
             carbonate,within 7 days prior to the first dose of study drug

          -  Patients with a life expectancy of less than 3 months

          -  Patients who are severely physically or mentally incapacitated and who in the opinion
             of investigator are unable to perform the subjects' tasks associated with the
             protocol

          -  Female patients who are pregnant, lactating, or planning to become pregnant

          -  Patients with diabetic ketoacidosis

          -  Presence of any condition which, in the opinion of the investigator, places the
             patient at undue risk or potentially jeopardizes the quality of the data to be
             generated

          -  Known hypersensitivity or previous anaphylaxis to ZS or to components thereof

          -  Patients with cardiac arrhythmias that require immediate treatment

          -  Patients on dialysis

          -  Patients who are blood donors should not donate blood during the study and for 3
             months following their last dose of ZS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiba-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hanyu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hitachinaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ina-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kanazawa-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koga-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsudo-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shimajiri-gun</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shizuoka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toride-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toyohashi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yao-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucheon-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cheongju-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hwaseong-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwon-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uijeongbu-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wonju-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hualien City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 23, 2017</lastchanged_date>
  <firstreceived_date>July 22, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperkalemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
